Do analysts recommend XCUR or BYSI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is XCUR or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% BeyondSpring N/A N/A -14.00%

Do analysts rate MCRB or XCUR?

Seres Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 116.15%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Seres Therapeutics is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MCRB or XCUR more profitable?

Seres Therapeutics' return on equity of -130.29% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics N/A -130.29% -35.35% Exicure N/A -179.41% -64.37%

Does the media favor MCRB or XCUR?

In the previous week, Seres Therapeutics had 2 more articles in the media than Exicure. MarketBeat recorded 5 mentions for Seres Therapeutics and 3 mentions for Exicure. Seres Therapeutics' average media sentiment score of 1.03 beat Exicure's score of 0.63 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exicure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate XCUR or MNOV?

MediciNova has a consensus target price of $8.33, indicating a potential upside of 472.74%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has better earnings and valuation, XCUR or MNOV?

Exicure has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exicure $500K 25.10 -$4.95M -$1.55 N/A MediciNova $410K 174.67 -$12M -$0.23 N/A

Is XCUR or MNOV more profitable?

Exicure has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% MediciNova -1,962.98% -27.28% -25.24%

Does the media prefer XCUR or MNOV?

In the previous week, MediciNova had 2 more articles in the media than Exicure. MarketBeat recorded 5 mentions for MediciNova and 3 mentions for Exicure. Exicure's average media sentiment score of 0.63 beat MediciNova's score of 0.52 indicating that Exicure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend XCUR or CYPH?

Cypherpunk Technologies has a consensus target price of $0.90, suggesting a potential upside of 30.68%. Given Cypherpunk Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Cypherpunk Technologies is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is XCUR or CYPH more profitable?

Cypherpunk Technologies' return on equity of -48.33% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Cypherpunk Technologies N/A -48.33% -42.21%

Do analysts rate XCUR or CING?

Cingulate has a consensus target price of $27.33, indicating a potential upside of 380.88%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is XCUR or CING more profitable?

Exicure's return on equity of -179.41% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Cingulate N/A -365.15% -158.55%

Does the media refer more to XCUR or CING?

In the previous week, Exicure and Exicure both had 3 articles in the media. Cingulate's average media sentiment score of 1.05 beat Exicure's score of 0.63 indicating that Cingulate is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cingulate 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Exicure (XCUR) Competitors

$1.97 -0.11 (-5.29%)

As of 11:35 AM Eastern

Compare

XCUR vs. BYSI, MCRB, MNOV, CYPH, and CING

Should you buy Exicure stock or one of its competitors? MarketBeat compares Exicure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exicure include BeyondSpring (BYSI), Seres Therapeutics (MCRB), MediciNova (MNOV), Cypherpunk Technologies (CYPH), and Cingulate (CING). These companies are all part of the "pharmaceutical products" industry.

How does Exicure compare to BeyondSpring?

Exicure (NASDAQ:XCUR) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

42.8% of Exicure shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Exicure had 2 more articles in the media than BeyondSpring. MarketBeat recorded 3 mentions for Exicure and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.87 beat Exicure's score of 0.63 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
Exicure	Positive
BeyondSpring	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Exicure has a beta of 3.53, meaning that its stock price is 253% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market.

BeyondSpring has higher revenue and earnings than Exicure. BeyondSpring is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	25.10	-$4.95M	-$1.55	N/A
BeyondSpring	$1.75M	41.35	-$1.01M	-$0.14	N/A

BeyondSpring's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
BeyondSpring	N/A	N/A	-14.00%

Summary

BeyondSpring beats Exicure on 7 of the 12 factors compared between the two stocks.

How does Exicure compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Seres Therapeutics' return on equity of -130.29% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Exicure	N/A	-179.41%	-64.37%

Seres Therapeutics has a beta of 0.13, suggesting that its stock price is 87% less volatile than the broader market. Comparatively, Exicure has a beta of 3.53, suggesting that its stock price is 253% more volatile than the broader market.

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 52.8% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Seres Therapeutics has higher revenue and earnings than Exicure. Seres Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	96.37	$5.70M	-$5.17	N/A
Exicure	$500K	25.10	-$4.95M	-$1.55	N/A

Seres Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 116.15%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Seres Therapeutics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Seres Therapeutics had 2 more articles in the media than Exicure. MarketBeat recorded 5 mentions for Seres Therapeutics and 3 mentions for Exicure. Seres Therapeutics' average media sentiment score of 1.03 beat Exicure's score of 0.63 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Seres Therapeutics beats Exicure on 11 of the 15 factors compared between the two stocks.

How does Exicure compare to MediciNova?

Exicure (NASDAQ:XCUR) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Exicure has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
MediciNova	-1,962.98%	-27.28%	-25.24%

MediciNova has a consensus target price of $8.33, indicating a potential upside of 472.74%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Exicure has a beta of 3.53, indicating that its stock price is 253% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

In the previous week, MediciNova had 2 more articles in the media than Exicure. MarketBeat recorded 5 mentions for MediciNova and 3 mentions for Exicure. Exicure's average media sentiment score of 0.63 beat MediciNova's score of 0.52 indicating that Exicure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

42.8% of Exicure shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 14.0% of MediciNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Exicure has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	25.10	-$4.95M	-$1.55	N/A
MediciNova	$410K	174.67	-$12M	-$0.23	N/A

Summary

MediciNova beats Exicure on 9 of the 17 factors compared between the two stocks.

How does Exicure compare to Cypherpunk Technologies?

Exicure (NASDAQ:XCUR) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

42.8% of Exicure shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cypherpunk Technologies has lower revenue, but higher earnings than Exicure. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	25.10	-$4.95M	-$1.55	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Cypherpunk Technologies' return on equity of -48.33% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

Cypherpunk Technologies has a consensus target price of $0.90, suggesting a potential upside of 30.68%. Given Cypherpunk Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Cypherpunk Technologies is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Exicure has a beta of 3.53, suggesting that its share price is 253% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

In the previous week, Exicure had 2 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 3 mentions for Exicure and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.89 beat Exicure's score of 0.63 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Exicure	Positive
Cypherpunk Technologies	Very Positive

Summary

Cypherpunk Technologies beats Exicure on 8 of the 14 factors compared between the two stocks.

How does Exicure compare to Cingulate?

Exicure (NASDAQ:XCUR) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Exicure's return on equity of -179.41% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Cingulate	N/A	-365.15%	-158.55%

Cingulate has a consensus target price of $27.33, indicating a potential upside of 380.88%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

42.8% of Exicure shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 52.8% of Exicure shares are owned by insiders. Comparatively, 5.3% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Exicure and Exicure both had 3 articles in the media. Cingulate's average media sentiment score of 1.05 beat Exicure's score of 0.63 indicating that Cingulate is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cingulate	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exicure has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	25.10	-$4.95M	-$1.55	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

Exicure has a beta of 3.53, meaning that its share price is 253% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.85, meaning that its share price is 185% less volatile than the broader market.

Summary

Exicure beats Cingulate on 9 of the 13 factors compared between the two stocks.

Get Exicure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XCUR vs. The Competition

Export

Metric	Exicure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.55M	$3.66B	$6.81B	$12.57B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-1.27	21.44	27.52	25.33
Price / Sales	25.10	339.00	539.41	102.00
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	3.18	8.75	10.94	6.61
Net Income	-$4.95M	$23.87M	$3.57B	$336.72M
7 Day Performance	-26.77%	3.51%	2.69%	2.63%
1 Month Performance	-40.84%	3.56%	1.84%	0.24%
1 Year Performance	-67.70%	67.21%	36.35%	29.97%

Exicure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XCUR Exicure	1.0028 of 5 stars	$1.97 -5.3%	N/A	-70.5%	$12.55M	$500K	N/A	50	News Coverage Gap Down
BYSI BeyondSpring	0.2578 of 5 stars	$1.62 +0.4%	N/A	-25.5%	$66.45M	$1.75M	N/A	80	Positive News Gap Up
MCRB Seres Therapeutics	3.9536 of 5 stars	$6.83 -3.2%	$17.00 +149.1%	-29.0%	$66.07M	$790K	N/A	330	Positive News Short Interest Decrease
MNOV MediciNova	3.2502 of 5 stars	$1.33 -2.2%	$8.33 +526.6%	+0.8%	$65.46M	$596.64K	N/A	10	News Coverage Short Interest Decrease Gap Up
CYPH Cypherpunk Technologies	1.1014 of 5 stars	$0.61 -6.5%	N/A	+106.2%	$64.95M	N/A	N/A	40	Positive News Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XCUR) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exicure (XCUR) Competitors

XCUR vs. BYSI, MCRB, MNOV, CYPH, and CING

How does Exicure compare to BeyondSpring?

Summary

How does Exicure compare to Seres Therapeutics?

Summary

How does Exicure compare to MediciNova?

Summary

How does Exicure compare to Cypherpunk Technologies?

Summary

How does Exicure compare to Cingulate?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exicure (XCUR) Competitors

XCUR vs. BYSI, MCRB, MNOV, CYPH, and CING

How does Exicure compare to BeyondSpring?

Do institutionals & insiders have more ownership in XCUR or BYSI?

Does the media prefer XCUR or BYSI?

Do analysts recommend XCUR or BYSI?

Which has more volatility & risk, XCUR or BYSI?

Which has preferable earnings and valuation, XCUR or BYSI?

Is XCUR or BYSI more profitable?

Summary

How does Exicure compare to Seres Therapeutics?

Is MCRB or XCUR more profitable?

Which has more volatility & risk, MCRB or XCUR?

Do institutionals and insiders hold more shares of MCRB or XCUR?

Which has higher earnings & valuation, MCRB or XCUR?

Do analysts rate MCRB or XCUR?

Does the media favor MCRB or XCUR?

Summary

How does Exicure compare to MediciNova?

Is XCUR or MNOV more profitable?

Do analysts rate XCUR or MNOV?

Which has more risk and volatility, XCUR or MNOV?

Does the media prefer XCUR or MNOV?

Do institutionals & insiders believe in XCUR or MNOV?

Which has better earnings and valuation, XCUR or MNOV?

Summary

How does Exicure compare to Cypherpunk Technologies?

Do insiders and institutionals believe in XCUR or CYPH?

Which has higher earnings and valuation, XCUR or CYPH?

Is XCUR or CYPH more profitable?

Do analysts recommend XCUR or CYPH?

Which has more volatility and risk, XCUR or CYPH?

Does the media prefer XCUR or CYPH?

Summary

How does Exicure compare to Cingulate?

Is XCUR or CING more profitable?

Do analysts rate XCUR or CING?

Do insiders & institutionals have more ownership in XCUR or CING?

Does the media refer more to XCUR or CING?

Which has preferable valuation and earnings, XCUR or CING?

Which has more volatility and risk, XCUR or CING?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools